Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Massachusetts
Clinical trial register · United States · industry-sponsored

Clinical Trials in Massachusetts, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 231 Florida 173 Arizona 113 Illinois 108 Georgia 104
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca67 Novartis Pharmaceuticals66 Eli Lilly and Company52 AbbVie39 Bristol-Myers Squibb35 Clear sponsor filter
State
California231 Florida173 Arizona113 Illinois108 Georgia104
All 48 states
Target enrolment
to

Trials with a site in Massachusetts

67 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
AstraZeneca
Phase 3
915
Arkansas, California, Illinois, Massachusetts, Missouri, Nebraska, New York, Ohio
2026-07-16
Recruiting
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
NCT07690436Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Observational
500
California, Florida, Illinois, Massachusetts, Oregon, Tennessee
2026-07-08
Recruiting
AstraZeneca
Phase 3
900
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2026-07-06
Active, closed
AstraZeneca
Phase 2
326
California, Colorado, District of Columbia, Florida, Illinois, Massachusetts, Missouri, New York
2026-06-11
Recruiting
AstraZeneca
Phase 2
80
Massachusetts, North Carolina
2026-06-04
Recruiting
AstraZeneca
Phase 3
420
California, Colorado, Connecticut, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2026-05-05
Recruiting
AstraZeneca
Phase 2
69
California, Florida, Kentucky, Louisiana, Massachusetts, Missouri, Ohio, Oklahoma
2026-04-14
Recruiting
AstraZeneca
Phase 2
124
Arizona, California, Kansas, Maryland, Massachusetts, Michigan, New York, North Carolina
2026-02-10
Recruiting
AstraZeneca
Phase 1/2
283
Arkansas, California, Maryland, Massachusetts, Michigan, New York, Rhode Island, South Carolina
2025-10-01
Recruiting
AstraZeneca
Phase 1/2
52
Florida, Massachusetts, Michigan, New York, Rhode Island
2025-09-30
Recruiting
AstraZeneca
Phase 3
250
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Mississippi
2025-08-07
Recruiting
AstraZeneca
Phase 1/2
150
California, Florida, Georgia, Illinois, Maryland, Massachusetts, Missouri, New York
2025-04-21
Recruiting
AstraZeneca
Phase 1/2
304
California, Maryland, Massachusetts, Missouri, New Jersey, Texas
2025-03-27
Recruiting
AstraZeneca
Phase 2
80
Arizona, California, District of Columbia, Illinois, Maryland, Massachusetts, Minnesota, New Jersey
2025-03-12
Recruiting
AstraZeneca
Phase 1
136
California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska, New York
2025-03-10
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Massachusetts, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island
2025-01-30
Active, closed
AstraZeneca
Phase 3
181
California, Illinois, Massachusetts, Missouri
2024-12-03
Active, closed
AstraZeneca
Phase 3
310
California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Oklahoma, Texas
2024-09-30
Recruiting
AstraZeneca
Phase 1/2
174
California, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas, Washington
2024-09-18
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
California, Connecticut, District of Columbia, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2024-06-25
Active, closed
AstraZeneca
Phase 4
1,511
California, Kentucky, Massachusetts, Michigan, Minnesota, North Carolina, Pennsylvania, Texas
2024-05-10
Active, closed
AstraZeneca
Phase 2
103
California, District of Columbia, Florida, Georgia, Hawaii, Illinois, Maryland, Massachusetts
2024-04-04
Recruiting
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT06218914Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
AstraZeneca
Phase 1
108
California, Florida, Illinois, Kansas, Massachusetts, Missouri, New York, Oregon
2024-03-22
Recruiting
AstraZeneca
Phase 1/2
60
California, Florida, Georgia, Kansas, Massachusetts, Missouri, New Jersey, New York
2024-03-12
Active, closed
AstraZeneca
Phase 2
58
Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-02-13
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
DrugsAZD3470·Keytruda·Pembrolizumab
AstraZeneca
Phase 1/2
161
California, Florida, Georgia, Massachusetts, New York, Pennsylvania, Texas
2024-01-23
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Massachusetts
2023-12-20
Recruiting
AstraZeneca
Phase 1/2
226
California, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Virginia
2023-12-05
Recruiting
AstraZeneca
Phase 3
231
Alabama, Arizona, Arkansas, California, Georgia, Maryland, Massachusetts, Michigan
2023-08-24
Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma
AstraZeneca
Phase 1
45
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Oregon
2023-07-12
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
California, Colorado, Kentucky, Massachusetts, Michigan, Ohio, Oregon, Rhode Island
2023-06-05
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
DrugsAZD9592·Osimertinib·Leucovorin·Adrucil
AstraZeneca
Phase 1
190
California, Connecticut, District of Columbia, Illinois, Maryland, Massachusetts, New York, Pennsylvania
2022-12-21
Active, closed
AstraZeneca
Phase 3
607
Arizona, California, Colorado, Florida, Massachusetts, Minnesota, Missouri, New York
2022-09-12
Recruiting
AstraZeneca
Phase 2
454
California, Indiana, Kansas, Massachusetts, Michigan, New Jersey, New Mexico, New York
2022-09-06
Recruiting
AstraZeneca
Phase 1/2
695
California, Illinois, Massachusetts, New York, Oregon, Texas, Virginia
2022-06-24
Recruiting
AstraZeneca
Phase 2
630
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2022-04-14
Active, closed
AstraZeneca
Phase 2
126
California, Georgia, Idaho, Massachusetts, Michigan, New York, Oregon, Texas
2021-12-10
Active, closed
AstraZeneca
Phase 3
148
Massachusetts, New York
2021-10-28
Active, closed
AstraZeneca
Phase 3
454
Alaska, California, Maryland, Massachusetts, Michigan, New Jersey, New York, Pennsylvania
2021-10-28
Recruiting
AstraZeneca
Phase 1/2
460
California, Louisiana, Maryland, Massachusetts, Missouri, New Mexico, New York, North Carolina
2021-10-18
Active, closed
AstraZeneca
Phase 3
732
California, Florida, Georgia, Massachusetts, Michigan, New York, Ohio, Oregon
2021-10-18
Active, closed
AstraZeneca
Phase 3
98
Maryland, Massachusetts
2021-09-12
Active, closed
AstraZeneca
Phase 3
506
Massachusetts, North Carolina
2021-06-22
Active, closed
AstraZeneca
Phase 3
893
Arizona, California, Colorado, Connecticut, Delaware, Kentucky, Maryland, Massachusetts
2021-05-10
Active, closed
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
102
California, Indiana, Massachusetts, New Jersey, New York, Texas, Virginia
2020-12-30
Active, closed
AstraZeneca
Phase 3
358
California, Massachusetts, New Hampshire, New York, Texas, Virginia, Washington
2020-12-16
Active, closed
AstraZeneca
Phase 3
957
California, Florida, Indiana, Kentucky, Massachusetts, New York, Tennessee, Texas
2020-11-17
Active, closed
AstraZeneca
Phase 1/2
702
Massachusetts, New York, Oklahoma, Texas
2020-11-12
Active, closed
AstraZeneca
Phase 3
370
Arizona, Illinois, Kansas, Massachusetts, Michigan, Minnesota, Missouri, Nevada
2020-10-02
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
California, Illinois, Indiana, Massachusetts, New Jersey, New York, North Carolina, Texas
2020-08-18
Active, closed
AstraZeneca
Phase 2
452
Maryland, Massachusetts, New York, Texas
2020-06-03
Active, closed
AstraZeneca
Phase 3
818
Arizona, California, Florida, Kansas, Maryland, Massachusetts, Minnesota, Missouri
2020-04-16
Active, closed
AstraZeneca
Phase 3
587
California, Florida, Kansas, Kentucky, Massachusetts, Nevada, New York, Ohio
2019-07-02
Active, closed
AstraZeneca
Phase 2
247
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, New York, Oregon
2019-06-25
Active, closed
AstraZeneca
Phase 3
810
California, District of Columbia, Florida, Kansas, Kentucky, Massachusetts, Missouri, North Carolina
2019-04-16
Active, closed
Durvalumab and Tremelimumab for Pediatric Malignancies
NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
DrugDurvalumab
AstraZeneca
Phase 1/2
50
Maryland, Massachusetts, New York, Oklahoma, South Carolina
2019-03-07
Active, closed
AstraZeneca
Phase 2
367
California, District of Columbia, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Washington
2019-01-09
Active, closed
AstraZeneca
Phase 1/2
243
Arizona, Maryland, Massachusetts, Michigan, Missouri, Texas, Virginia
2018-12-21
Active, closed
AstraZeneca
Phase 2
528
California, District of Columbia, Illinois, Maryland, Massachusetts, Missouri, New York, Pennsylvania
2017-12-18
Active, closed
Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT03091192Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms
DrugsSavolitinib·Sunitinib
AstraZeneca
Phase 3
60
California, Georgia, Illinois, Iowa, Massachusetts, Missouri, New York, Tennessee
2017-07-25
Active, closed
AstraZeneca
Phase 1/2
264
Georgia, Maryland, Massachusetts, Michigan, Missouri, Ohio, Pennsylvania
2016-03-17
Active, closed
AstraZeneca
Phase 3
1,126
California, Colorado, Connecticut, Florida, Georgia, Kentucky, Massachusetts, Michigan
2015-11-02
Active, closed
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
DrugsSaruparib·Olaparib·Durvalumab·Carboplatin
AstraZeneca
Phase 1
358
California, Massachusetts, New York, Pennsylvania
2014-10-31
Active, closed
AstraZeneca
Phase 1
344
Georgia, Massachusetts, New York, Pennsylvania, Tennessee
2014-08-05
Active, closed
AstraZeneca
Phase 3
510
Colorado, Florida, Georgia, Illinois, Louisiana, Massachusetts, New York, North Carolina
2013-09-25
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Alabama, California, Colorado, Connecticut, Florida, Illinois, Maryland, Massachusetts
2013-09-03
Active, closed
AstraZeneca
Phase 2
162
California, Florida, Indiana, Massachusetts, New York, Oregon
2010-02-04
Rows per page Showing 1–67 of 67
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/state/massachusetts

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 67 of those studies with a site in Massachusetts that also match the filters currently applied.

How many clinical trials are recruiting in Massachusetts?

29 of the 67 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 38 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Massachusetts), 67 studies
PhaseStudiesRecruitingShare
Phase 324535.8%
Phase 217625.4%
Phase 1/2161223.9%
Phase 1639%
Observational334.5%
Phase 4101.5%

Most active sponsors

Lead sponsors with the most studies (Massachusetts)
Lead sponsorStudiesRecruiting
AstraZeneca6729
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.